ELAN Q3 2020 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$890M+15.3% YoY

Gross Profit

$352M39.6% margin

Operating Income

-$14M-1.5% margin

Net Income

-$135M-15.2% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+51.7%

Cash Flow

Operating Cash Flow

-$112M

Free Cash Flow

-$216M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$17.2B

Total Liabilities

$8.9B

Stockholders' Equity

$8.3B

Cash & Equivalents

$660M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$890M	$771M	+15.3%
Gross Profit	$352M	$360M	-2.2%
Operating Income	-$14M	$98M	-113.9%
Net Income	-$135M	$10M	-1450.0%

Revenue Segments

Pet Health Disease Prevention

$297M33%

Farm Animal Ruminants And Swine

$292M33%

Farm Animal Future Protein And Health

$181M20%

Pet Health Therapeutics

$103M12%

Contract Manufacturing

$16M2%

Geographic Segments

Non-US

$468M53%

UNITED STATES

$422M47%